Human stem cells, progenitor cells, and cell lines have been derived from embryonic, fetal, and adult sources in the search for graft tissue suitable for the treatment of CNS disorders. An increasing number of experimental studies have shown that grafts from several sources survive, differentiate into distinct cell types, and exert positive functional effects in experimental animal models, but little attention has been given to developing cells under conditions of good manufacturing practice (GMP) that can be scaled up for mass treatment. The capacity for continued division of stem cells in culture offers the opportunity to expand their production to meet the widespread clinical demands posed by neurodegenerative diseases. However, maintaining stem cell division in culture long term, while ensuring differentiation after transplantation, requires genetic and/ or oncogenetic manipulations, which may affect the genetic stability and in vivo survival of cells. This review outlines the stages, selection criteria, problems, and ultimately the successes arising in the development of conditionally immortal clinical grade stem cell lines, which divide in vitro, differentiate in vivo, and exert positive functional effects. These processes are specifically exemplified by the murine MHP36 cell line, conditionally immortalized by a temperature-sensitive mutant of the SV40 large T antigen, and cell lines transfected with the c-myc protein fused with a mutated estrogen receptor (c-mycER TAM ), regulated by a tamoxifen metabolite, but the issues raised are common to all routes for the development of effective clinical grade cells.
INTRODUCTION
tegrating into host brain structures (29). Although primary fetal grafts have provided "proof of principle" for the therapeutic efficacy of CNS transplant treatments, Transplantation of multipotent stem cell lines, capable of differentiating into all CNS cell types, provides slow throughput arising chiefly from scarcity of tissue has meant that this method can only be experimental in an attractive possibility for treating brain damage and disorders. Previous studies have shown that grafted pri-nature, and never meet the demands of huge unmet clinical needs. mary fetal cells survive and exert positive effects in animal models of Parkinson's (PD), Alzheimer's (AD), and
In contrast, stem cells, which can be grown in unlimited numbers in culture, have the potential to deliver Huntington's (HD) diseases (3, 4, 6, 26, 84) and ischemic brain damage (67, 69) . Clinical trials have also shown treatment on a mass scale. Advantages of stem cells include the possibility of developing fully screened clonal limited improvements of symptoms in PD patients (50), though with some risk of exacerbation (18), and promis-lines to ensure the uniformity and purity of grafted cells, chances to graft cells in an undifferentiated state, to ing safety trials in HD patients have been initiated (82) . However, primary fetal tissue has widely acknowledged allow the host brain to guide their development, the possibility of transfecting stem cells with genes to maintain drawbacks as a source of cells for grafting. These include requirements for several donor fetuses, which in-division, bias them towards a particular mature phenotype, or to deliver therapeutic genes (e.g., to correct ge-crease logistical problems and graft heterogeneity in transplant surgery, ethical concerns about use of fetal netic defects or attack tumors) (29, 51, 71) . Because clonal lines or expanded populations can be derived material, limited time frames for screening donors and cells, and the tendency of grafted cells to remain from relatively few stem cells, ethical and practical concerns that encumber primary cell grafts are reduced. One clumped around the site of implantation, rather than in-of the most striking features of stem cells is their ability be further along the route to differentiation than ES cells, and are sometimes described as precursor or pro-to migrate to sites of damage into the host brain, and to integrate seamlessly into host structures, so that they do genitor cells, but they are multipotential (capable of differentiating into neurons, astrocytes, and oligodendro-not exhibit graft masses shown by primary cell transplants (28, 29) . These advantages have encouraged the cytes in vitro and in vivo) and express the stem cell marker nestin (49, 91) . At present, fetal CNS tissue, do-development of stem cell lines as a preferable therapeutic alternative. However, a number of problems have nated from terminations under strict ethical guidelines, provides the most accessible source for neural stem cells arisen during the development of stem cell lines, which have significantly delayed progress and focused atten-and is receiving increasing research attention in vitro and in animal models (13, 17, 43, 70, 95) . tion on the necessary stages of progress and conditions that have to be met for successful generation of clinical
The adult brain continues to generate stem cells in particular regions such as the hippocampal dentate gyrus grade cell lines (21). This review outlines in principle the main stages, questions to be addressed, and problems and subventrivular zone (44), but even though new neurons are increased after injury or ischemia (38, 44, 53, 66) , arising in the development of stem cell lines, exemplified in particular by the murine MHP36 line developed these are not sufficient to stimulate endogenous repair, as occurs with some peripheral tissues. In the future, at the Institute of Psychiatry as "proof of principle" and the CTX0E03 line developed by ReNeuron Ltd in methods may be developed to stimulate injury-induced neurogenesis, by infusion of growth factors (40, 66) , Guildford as a potential clinical grade line. Specific details of tissue dissection, transfection, and culture condi-which can occur not only in neurogenic regions, but also in striatal, septal, and thalamic parenchyma (74) . Adult tions have been reported for MHP36 (85) and CTX0E03 (75) cell lines.
stem cells for grafting are obtained from many sources: bone marrow (stromal and hematopoetic stem cells), CHOICE OF STEM CELLS skin, umbilical cord blood, and from cadaveric CNS (11, 12, 19, 39, 73) . There has been considerable interest in Most investigations of stem cell harvesting, culture, and grafting have used rodent cells grafted into rodents.
showing that adult stem cells from blood or bone marrow can transdifferentiate into neural phenotypes within However, for clinical development, it is preferable to use human cells, as pioneered by primary fetal grafts in a CNS environment (94), suggesting that considerable plasticity remains in cells apparently committed to dis-PD and HD patients (50, 82) . Human stem cells are grafted into animals (mainly rodents) for essential pre-parate lineages. However, alternative mechanisms in terms of hybrid or fused cells (90, 99) have called into clinical studies, even though this raises a host of complications in interpreting and translating the findings to question the significance of transdifferentiation. Adult stem cells have been shown to survive in ro-clinical outcomes. Major problems center around species differences in anatomy, physiology, and immune re-dent brain, even when administered by peripheral routes such as a tail vein, to differentiate into different neural sponse, and the growth and migration characteristics of human cells in the different microenvironments of small cell types, and to promote functional improvements in rats with ischemic brain damage (11, 12, 19, 39, 100) . Adult rodent and large human brain (21). Hence, in vivo assessment of human stem cells is severely limited by bio-stem cells also possess the important potential for providing autologous grafts, which increases their appeal. logical constraints.
Stem cells are found in embryonic, fetal, and adult Overall, in the absence of a clear frontrunner, the choice of optimum source of cells for clinical development will tissue, so the first question is which source is most practical and appropriate for deriving potential clinical grade very likely reflect their current availability and the research expertise of a given laboratory. cells. Embryonic stem (ES) cells are obtained from the inner cell mass of the blastocyst, and use of human ES STEM CELL EXPANSION AND CONTROL cells has been licensed in the UK from spare embryos OF DIVISION left over from in vitro fertilization, for the first 2 weeks of development. ES cells are highly plastic, capable of Whatever their origin, use of stem cells presents a common set of problems, and some essential require-differentiation into all cell types of the developing endoderm, mesoderm, and ectoderm. However, human ments. The main advantage of dividing stem cells is that they can be expanded in vitro, to create bulk cultures sources are scarce and highly regulated, and optimum long-term culture conditions are still in the process of for large-scale use. However, stem cells in culture will eventually exit the cell cycle, unless division is main-development, so human ES cells are an imminent rather than a present resource. Neural stem cells, on the other tained by trophic stimulation or genetic modification. Once continuous or prolonged division has been initi-hand, from adult or fetal CNS tissue, are more readily available than ES cells. Neural stem cells are likely to ated in vitro, it then becomes mandatory to ensure that the cells are regulated so that they stop dividing in vivo, richment of TH+ cells within grafts has been the goal of many laboratories, and has been pursued using a variety and do not form tumors. Indeed, evidence from animal studies indicated that grafting fresh unmodified stem of culture conditions, treatment with antiapoptotic and anti-inflammatory agents, or cografting of trophic fac-cells led to tumor formation in approximately 20% of recipients (5), presenting an unacceptable risk. Even tors (7) , with some promising evidence for enhanced survival and efficacy, including primate models (89) . grafts of primary fetal cells are liable to overgrowth, possibly resulting from adventitious inclusion of divid-Kim et al. (45) made a significant breakthrough by showing that murine ES cells could be biased to a DA ing immature cells in dissections intended to harvest only early postmitotic cells (26) . The first requirements, fate by transfection with the Nurr1 gene. TH+ grafted cells survived in significant numbers, exhibited appro-therefore, are to devise methods of ensuring expansion (i.e., continued division) in vitro and differentiation (i.e., priate electrophysiological properties, and induced functional recovery from amphetamine-induced rotation bias limited or no division) in vivo. There have been four main approaches to these requirements: 1) to maintain and other motor dysfunctions. Similar strategies may be applicable to enrichment of other specialized cell types, stem cells as "epigenetic" lines in growth factor-rich media; 2) to predifferentiate or bias stem cells into a such as insulin-secreting cells for diabetes (54) . Predifferentiation or genetic bias provides an important ap-preferred mature cell type before grafting; 3) to make stem cells "conditionally immortal" by transfection with proach for conditions associated with loss of specific cells (51), but would be less relevant to conditions such an oncogene that maintains division in vitro, but permits differentiation in vivo; and 4) to regulate in vitro onco-as stroke, where damage is indiscriminate. It also fails to take advantage of the defining multipotential capacity gene-driven division by fusion with a receptor selectively responsive to a ligand available in vitro, but not of stem cells, whereby the damaged brain directs differentiation along appropriate routes. Hence, techniques for in vivo.
The earliest approach to long-term stem cell culture implanting cells in a stem-like state have also been actively pursued. has been to maintain cells in growth factor-rich media.
Both rodent and human cells respond to epidermal
Conditional immortalization involves transfection of cells with immortalizing oncogenes (56) , to permit cell growth factor (EGF) and fibroblast growth factor (FGF-2) (9,20,41,93,95) and can be cultured as monolayers or division in vitro, but not in vivo. For example, the temperature-sensitive (ts) mutant allele (tsA58) of the sim-free-floating neurospheres. Grafted human neurospheres (70) or relatively unexpanded progenitor cells (17) sur-ian virus 40 large T antigen (SV40 TAg) maintains stem cells in continued division in cold (33°C) culture condi-vive long term, extend long processes, and cease to divide after grafting, so that they integrate well into rat tions, but switches off division at a higher brain-like temperature (37-39°C), allowing cells to differentiate brain, and appear to be safe. However, no reduction in amphetamine-induced rotation bias was seen in a unilat-into mature phenotypes after grafting. Clonal cell lines developed from the fetal neuroepithelial (E14) tissue eral nigrostriatal lesion model of PD (70) , and in general, positive functional effects are lacking with epige-from the H-2K b -tsA58 transgenic mouse (36) or by transfection of human fetal (week 8-12) cortical and netic lines. Neurospheres contain mixed populations of cells at differing stages of development, which has ren-striatal cells, using replication-incompetent retroviral vectors, have shown successful conditional immortaliza-dered the epigenetic route of stem cell expansion less attractive for clinical development, where the aim has tion, with cells dividing in culture, and differentiating into all CNS cell types at higher temperatures in vitro been to develop uniform expanded clonal cell lines of known lineages. and in vivo (59, 85) . Moreover, because clonal lines are derived from a single parent cell, they are thought likely Differentiation of stem cells before grafting or biasing cells towards a specific mature phenotype avoids the to remain uniform and consistent across passages. Temperature-sensitive immortalized cells therefore appeared risk of continued division in vivo, and provides the exciting possibility of grafts enriched for particular cell to meet the initial requirement for expandable, but safe, stem cell lines. types, notably dopaminergic (DA) cells for treatment of PD. Grafting of primary mesencephalic fetal tissue for Other routes for regulated immortal stem cell lines have been developed using myc oncogenes (95), either PD has suffered from low survival of DA cells in vivo (typically 5-10%). Grafting of unmodified ES cells, c-myc (cellular myc) or v-myc (viral myc), shown to play an important role in normal and neoplastic cell prolifera-while providing sufficient numbers of tyrosine hydroxylase-positive (TH+) cells to promote recovery from mo-tion, differentiation and apoptosis (14). Littlewood et al.
(52) showed that myc could be made functionally depen-tor asymmetry (as shown by amphetamine-induced rotation bias) resulted in tumor formation in 20% of dent on the synthetic oestrogen receptor ligand tamoxifen (4-OHT), by fusion with a mutant murine estrogen animals, so would not be clinically appropriate (5). En-receptor (ER). In the presence of tamoxifen and growth factors (EGF and bFGF), myc remains transcriptionally active in the cell nucleus, maintaining cell division, but when tamoxifen and growth factors are withdrawn, either in vitro or after grafting, mycER translocates to the cytoplasm, and normal differentiation is resumed (30, 75) . Use of an inactive mutant estrogen receptor means that mycER is not responsive to hormonal estrogen; hence, any future therapeutic tamoxifen treatment of graft recipients would not affect mycER activity in differentiated grafted cells. We have created approximately 100 regulated immortal human c-mycER TAM stem cell lines (30) using c-myc. Table 1 outlines steps to generate human stem cell lines to exploit unlimited growth and capacity, while ensuring safety after grafting. Once stem cell lines have been generated under conditions of good laboratory lead lines to progress towards banking and clinical trials ( Fig. 1 ).
Conditionality

IN VITRO STUDIES
Assessment of control of growth in vitro is essential In vitro studies aim to determine growth characteristo establish that cell division is conditional. With ts tics, confirm conditionality and multipotentiality of lines, lines, raising the temperature from 33°C to 37°C causes check that their karyotype is normal and stable, and excell numbers to plateaux, and cells differentiate into neuamine their molecular phenotype. rons (ϳ20%), glia (ϳ60%), and more rarely oligodendrocytes (ϳ10%), over 5-10 days in vitro. Nestin ex-Growth Kinetics pression is lost within 1-2 h, by proteasome degradation signaled by Notch (59), indicating rapid loss of stem cell Growth kinetics, measurable by cell proliferation status. In the case of c-MycER TAM lines, when both assay (DNA-Cyquant) and counting cells in flasks at growth factors (EGF and bFGF) and tamoxifen are witheach successive passage, were used to establish whether drawn, expansion stops, and a steady state is reached in rate of expansion is sufficient for scaling up of produc-3-4 days (75) . If either growth factors or tamoxifen are tion to establish master and working banks, and eventuwithdrawn singly, doubling time slows from 36-48 h to ally to meet clinical demands. The c-MycER TAM lead line 5-6 days, indicating that both are needed for optimum CTX0E03, for example, showed an overall doubling proliferation. However, proliferation was not affected by time of 50-60 h, allowing for a 50-fold expansion in 3 inclusion of a high concentration of 17-β-estradiol in the weeks (75) . Slower growing lines are feasible, but remedium, indicating insensitivity of the artificial ER to quire a longer development time. hormonal estrogen.
Differentiation Table 1. Generation of Human Stem Cell Lines
It is important to confirm stem cell identity and differentiation. During growth, c-MycER TAM cells stained cytic (GFAP positive), but CNPase staining for oligo-efficacy and provide a valuable tool for selecting lines with therapeutic potential. With c-MycER TAM lines we dendrocytes was typically low, as in the MHP lines. CTX0E03 cells predominantly differentiated into neu-identified 15 genes across approximately 100 lines by RT-PCR (30), a laborious process that relies on best rons.
guesses to select genes that might discriminate between Karyotype Stability effective and ineffective lines. However, mass screening by gene chip analysis could, in principle, provide a far Transfection of cells with genes of interest carries a risk of affecting their genetic stability. Of prime concern more efficient tool to characterize and cross-reference cell lines more fully in the future. is that karyotype will become abnormal and unstable, possibly through shortening of telomeres over passages.
Future Developments Genetic instability undermines the aim of producing cells for grafting that are consistent and identical from Future developments could take many directions, depending on available funding and scientific develop-patient to patient. Both murine and human ts lines carrying the SV40 TAg oncogene showed genetic instability ments. A fuller characterisation of the molecular phenotype of cell lines, and development of further frontrunner with chromosomal abnormalities that varied between lines, and from passage to passage, and hence were not lines are immediate starting points. Genetic and epigenetic modifications to improve the survival and differen-suitable for progression to clinical grade lines. This underlines the importance of setting up clear in vitro tiation of cells, and particularly to enrich dopaminergic differentiation, are under investigation. screening criteria to make early decisions about whether to continue or terminate the development of candidate Discovery of factors that will improve proliferation, differentiation, survival, and migration of cells (20,41), lines. In contrast to ts lines, G-banding analysis of dividing cells fixed in log phase growth and identified by will enhance understanding of signaling pathways that guide the positioning and differentiation of cells in host staining with BrdU (75) has shown that most of the c-MycER TAM lines are genetically normal (23 pairs of brain. Packaging of neuroprotective or neurotrophic factors into viral vectors used for immortalization may also chromosomes) and stable from early to late passages (e.g., p10 to p45 for the CTX0E03 line). Moreover, the enhance survival of grafted cells and host brain plasticity, combining advantages of gene transfer with cell activity of telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase, which is important for grafting (71) . For example, inclusion of heatshock protein 72 (42) or growth factor genes (2), might protect maintaining telomere length over cell divisions, was dose-dependently increased by tamoxifen in CTX0E03 grafted and host cells, increase host neurogenesis (66, 74) , and survival of grafted cells. The second gener-cells. Because myc upregulation of TERT is thought to be a key mechanism for maintaining genetic stability ation of stem cell lines is likely to take more informed advantage of plastic and regenerative processes in host across numerous cell divisions (10), this demonstration of tamoxifen's influence over c-myc-ER TAM -induced te-brain (72). Bioengineering techniques will also provide improved methods for growing and grafting cells. For lomerase activity suggests that the construct may actually enhance genetic stability (75) .
example, automated bioreactors would enable cells to be grown more efficiently in bulk; degradable scaffolds Molecular Phenotype would be advantageous for extensive damage, as in stroke, or for enabling grafts to bridge long distances in In our hands, analysis of the molecular phenotype of candidate cell lines represents part of the in vitro screen-spinal cord damage. Much effort will also be expended to formulate media and injection kits for the safe, uni-ing process that may yield important information, but has not yet been found to provide predictive criteria. form delivery of grafts in different surgical settings, without the need for tissue culture facilities. Detection of a range of genes associated with position specificity and differentiation (e.g., Musaschi, Hash1, IN VIVO STUDIES Pax6, Ngn1, Olig2, Dlx1, Sox2) expressed in stem cells indicates whether cells have a normal molecular profile Once genetic stabiliy and multipotentiality of candidate lines has been established, in vivo studies are un-consistent with their brain region of origin. However, MHP cell lines differed consistently both in functional dertaken to show that cells survive, migrate, and differentiate in living brain. After this, long-term studies of efficacy and in expression of genes. For example, highly effective lines such as MHP36 were Pax6 negative, functional effects in animal models of neurodegenerative disorders require investigation as indicators for clin-whereas less effective lines such as MHP15 were positive (76). Therefore, correlations of molecular and be-ical applications and "proof of principle." Our in vitro screening process whittled down approximately 100 c-havioral profiles of grafts across a range of lines may show patterns of gene expression that predict functional MycER TAM lines to approximately 16 (eight cortical, eight striatal) for short-term survival studies, and then to kine genes to downregulate immune response (e.g., TGFβ, IL-10) (77), engineering of grafted cells to express eight for behavioral investigation, from which a frontrunner emerged to bank for regulatory requirements (30) .
the recipient's genes encoding MHC, tolerization of the recipient, or the use of antibodies to MHC molecules.
Immunosuppression
These methods may not translate easily from rodent to human conditions, but at least the techniques can be de-When cells developed for transplantation are human, they will form xenografts in animal models and require veloped in animal models. an efficient and humane immunosuppression regime to Survival and Differentiation avoid rejection. The standard regime involves daily intraperitoneal (IP) injections with cyclosporine A (CSA),
We selected 2-and 5-week survival periods to show early and longer term survival of c-MycER TAM lines in which is stressful and labor intensive. It would be highly advantageous to develop reliable alternatives. Our cur-rats with unilateral quinolinic acid (QA) striatal lesions (used in behavioral studies as a partial model of HD). rent treatment involves subcutaneous (SC) injections of CSA (10 mg/kg) in cremaphor EL (Sigma UK) in a ratio Previous work with human and murine ts lines showed that poorly surviving grafts had largely vanished by 2 of 1:4 starting the day before graft surgery and continuing for 3 days/week until perfusion. In addition, rats are weeks (30) , whereas grafts that survived for 5 weeks were likely to persist throughout long-term (12+ weeks) injected daily SC with solumedron (n-methyl prednisolone) for 2 weeks, starting on the day of surgery. This behavioral studies. We chose a unilateral QA lesion (1.0 µl of a 0.08 M solution in PBS) that induces circum-provides stable blood levels of CSA in the range of 400-500 µg/L safely above the 200 µg/L level required scribed loss of specific cells (DARPP-32-positive medium spiny neurons) to examine cell survival in an intact for graft protection (Fig. 2Fig. 2) , and halves the number of injections. and damaged brain regions. Three weeks later rats were grafted in the intact and lesioned striatum, and in the However, a large (21 gauge, 0.8 mm diameter) needle is required for the viscous liquid, and care must be taken intact hippocampus, a total of 400,000 cells across six sites/rat. Lesions were estimated by the extent of loss of to pinch the puncture closed to prevent leakage, and to vary the site of injection to avoid nodules forming, so DARPP-32-positive neurons, grafted cells were identified by reactivity to human nuclear (HuNuc) staining, the treatment is not ideal. Other treatments, tolerizing neonatal pups by an injection of human tissue, or im-doubled labeled with neuronal and glial markers. Of the 16 lines investigated, six showed poor survival and dif-planting a slow release capsule of immunosuppressant into the brain before grafting (S.B. Dunnett, personal ferentiation, two were predominantly astrocytic, and the remaining lines showed mainly neuronal differentiation communication) may provide greater improvements.
A more serious problem for clinical development is (30) . Seven lines (three cortical, three striatal, and one hippocampal) were chosen for behavioral analysis. that the immunological response of rats to human cells will not shed much light on the fate of these cells in Proliferation human brain. Opinion is divided about the extent of MHC expression in stem cells. In MHP murine lines ex-Comparisons of the numbers of dividing cells, identified by Ki-67 staining, at 2 and 5 weeks, were undertaken pression was found to be low, mouse-to-rat grafts provoked little immune response, which was limited to the to compare continued division in myc-immortalized cells with and without the ER construct. CTX clone 26 (c-trauma of the injection tract (64), and graft rejection was not seen even in animals without CSA treatment. Howmyc alone) showed 2.2% of dividing cells at 2 weeks, which rose to 11% by 5 weeks. In contrast, c-MycER TAM ever, human neural stem cells have been found to express high levels of MHC class I (46) , raising the possibility that lines showed low and stable proliferation rates of approximately 0.5-3% at both time points. The CTX0E03 rejection may be higher than with mouse-derived grafts. Human tsT cells grafted in rat brain rarely survived be-lead line showed proliferation rate of 0.5% at 2 weeks and 2.3% at five weeks. These data will be systemati-yond 2 weeks (30) . The reasons are poorly understood, but rejection did not appear to play a major role. With cally replicated and taken to longer time points to confirm the ongoing safety of grafted c-mycER TAM cell lines. c-MycER TAM lines, expression of MHC is variable and does not appear to correlate with the extent graft sur-FUNCTIONAL EFFICACY OF GRAFTS: vival. The lead line CTX0E03 is positive for MHC class BASIC STUDIES AS PROOF OF PRINCIPLE I, but not class II, but the functional significance of this WITH MHP GRAFTS is not yet known. Selection criteria of future lines will likely include low MHC expression, to reduce immune
The choice of models and tests for initial screening of novel lines needs careful consideration, because models provocation. There are also several potential strategies to reduce graft rejection, including transfection of cyto-should be relevant to clinical conditions, and reasonably Mean ± SEM plasma levels of cyclosporin A (AxSYM fluorescence polarization immunoassay) in 37 rats, taken at weekly intervals over a period of 18 weeks following transplant (n = 19) or sham (n = 18) surgery. Samples were taken from all rats from the day of surgery for the first 3 weeks; after this half the rats provided samples on alternate weeks. CSA (10 mg/kg) in cremaphor EL in a ratio of 1:4 was injected SC three times a week, and n-methyl prednisolone (20 mg, SC) was injected daily for the first 2 weeks. This resulted in high stable CSA levels of 450-500 µg/L, well above the therapeutic level of 200 µg/L. At 8 weeks the dose of CSA was dropped to 9 mg/kg, and then to 8 mg/kg at 9 weeks, to reduce levels of CSA, without losing therapeutic efficacy, and to reduce the risk of elevating creatinine levels. Mean creatinine levels were 1.2 ± 0.2 µg/dl, within a safe range, although three rats showed higher levels and were given fluid injections and lower doses of CSA for short periods to reduce the risk of liver damage. Grafted rats received human fetal mesencephalic tissue and xenograft survival after 18 weeks of the CSA regime was 84%. Of the 3/19 rats failing to show graft survival, two had CSA levels below 200 µg/L, possibly resulting from formation of nodules at injection sites, which may have prevented dispersal, and one showed a low initial level of CSA, suggesting that maintenance of levels above the therapeutic threshold is critical, especially immediately after grafting. (Data from I. Reuter, in preparation) consistent to allow comparisons across experiments. Le-learning in the water maze (24, 67, 84) . Striatal lesions and stroke damage induced by MCAO disrupt both mo-sion models of PD, AD, or HD partially reflect the results, not processes or causes, of disease, but are useful tor and cognitive performance. For these two conditions we typically use a battery of tests: removal of sticky as screens because they are reproducible and use tests standardized in rats that provide easier targets for sur-tape from forepaws to detect sensory motor deficits, amphetamine-induced rotation bias and the body sway to gery than mice (3, 4) . Ischemic models in rats [e.g., middle cerebral artery occlusion (MCAO) for stroke and test for gross motor asymmetry, the staircase test for skilled paw reaching using fine motor control, and spa-four vessel occlusion (4VO) for global ischemia] more accurately reflect the cascade of processes initiated by tial learning in the water maze for cognitive function (61, 83) . This battery allows comparison of the extent interruption of cerebral blood flow that are common to rats and people, and behavioral outcomes have been rea-of graft-induced recovery across different functions and different experiments. sonably well characterized (15, 35, 60, 61, 69) . However, even with ischemic models, differences in reperfusion, Work with the ts MHP36 cell line showed clear positive effects of grafts in several animal models, providing brain size, and motor impairments affect the accuracy and predictive value of rodent models (15, 88) . not only proof of principle, but a gold standard for effects we hoped to achieve with clinical grade stem cell Different models require different types of functional assessment; cholinergic and hippocampal lesion or is-lines (22, 23) . Spatial learning in aged rats (27) and in animals with unilateral basal forebrain, a partial model chemic damage are reflected in impaired cognitive performance, measurable, for example, by impaired spatial for loss of cholinergic projections in AD (24), was im-proved by MHP36 grafts, whether lesions were unilat-cells (43). The precise alignment of MHP36 cells within regions of hippocampal damage, together with their eral or bilateral, and whether grafts were given 6 weeks or 6 months after lesioning (24) . Similarly, spatial learn-CA1-like firing pattern in response to electrophysiological stimulation of the host perforant path, and pheno-ing deficits in rats with selective loss of hippocampal (mainly CA1) cells induced by 4VO were reduced in typic resemblance to CA1 pyramidal cells has suggested that with this discrete lesion, stem cells act to repair the rats with MHP36 grafts, and improvement was more marked than in rats receiving the similar ts cells from damaged circuit (28, 81) . In contrast, damage produced by MCAO is extensive and indiscriminate, and grafted the MHP15 line (85) . In rats with unilateral QA lesions to mimic loss of GABAergic (DARPP-32+) output neu-MHP36 cells dispersed sparsely, but widely. When grafted in the intact striatum to avoid placing them in rons in HD (79) , paw reaching, tape removal, and amphetamine-induced rotation bias were all normalized, a hostile environment, cells dispersed both towards the stroke-damaged hemisphere and remained within the in-and MHP36-grafted rats were as efficient as controls in spatial learning. MHP15 grafts proved less successful tact side (92). Direct comparisons of grafts targeted both to the stroke-damaged and nonlesioned side (62) con-than MHP36 grafts in resolving behavioral deficits in "HD" rats, indicating that the reduced efficacy of the firmed that about a third of grafted cells crossed to the contralateral hemisphere, while two thirds dispersed in MHP15 line extended to different types of brain damage. Interestingly, the number of grafted cells differenti-the region of implantation, whether this was lesioned or not, although overall survival rates were higher when ating into a DARPP-32+ phenotype was lower in MHP15 than MHP36 grafts (29). Because the number of DARPP-cells were grafted contralateral to stroke damage. These findings indicated that grafts responded not only to sig-32+ cells correlated positively with the extent of behavioral recovery, particularly in the paw-reaching task of nals from regions of direct damage, but also to contralateral brain regions, suggested by neuroimaging studies in fine motor control (29), these results not only showed differential graft effects but also a strong relationship stroke patients (37) to be undergoing extensive reorganization following stroke. Because extensive lesions re-between a specific phenotype of grafted cells and behavioral recovery. mained in grafted animals, far too large for grafts to "fill the hole," repair mechanisms were more likely to in-MCAO induces large fluid filled cysts at the core, surrounded by a penumbra of partial cell loss and gliosis volve graft participation in host processes of reorganization and compensation, than repair of specific circuits. around the infarct. This ischemic damage contrasts starkly with the selective hippocampal cell loss induced Furthermore, in rats with long-term grafts (11 months) stroke volume was substantially reduced (92), though by 4VO, and is more extensive than striatal QA lesions. Nevertheless, rats with MHP36 grafts showed substan-this tendency was not significant at 3 months after grafting (62), suggesting that, in the long-term, grafts dimin-tial reduction of rotation and tape removal asymmetry (92). Water maze learning was not improved, unless ished slowly progressing thalamic degeneration that occurs after stroke, exerting delayed trophic effects. Hence, grafts were targeted to the ventricle, rather than the intact or damaged striatum (62) , indicating that large le-several graft mechanisms may combine and evolve over time, in response to ongoing lesion effects ( Table 2) . sions may require multiple implants, as suggested for primary fetal grafts (68) despite the greater migratory FUNCTIONAL EFFICACY capacity of stem cells.
OF CLINICAL GRADE GRAFTS: BASIC STUDIES WITH HUMAN c-MycER TAM LINES IMPLICATIONS FOR REPAIR MECHANISMS
We selected seven lines to graft in lesion models of A range of models provides the opportunity to assess AD (unilateral basal forebrain lesions), HD (unilateral graft potential for different degenerative and neurological conditions, and to see whether stem cells adapt in different ways to different types of brain damage, point- ited a range of repair mechanisms, and that different in rats (28) . types of brain damage engaged different mechanisms. damage has also been reported with human fetal stem quinolinic acid striatal lesions), global ischemia (20 min by a significant reduction in amphetamine-induced rotation bias (Fig. 4) , though not to control level. Cells were of 4VO), and focal ischemia (70 min of MCAO). Results and survival of cells were variable across lines (as grafted ipsilateral to occlusion, and had migrated from the injection tract and integrated into residual striatum. might be expected from differences between MHP15 and 36 grafts), but positive indications of efficacy Cells were mainly neuronal, as shown by colocalization of HuNuc staining with neurofilament antibody. In con-emerged for the CTX0E03 cell line across different lesion models, as occurred with MHP36 grafts. For exam-trast to MHP36 cells, there was no evidence for migration across the midline, but as with short-term MHP36 ple, CTX0E03 grafts substantially improved spatial learning in rats with 4VO damage, and improved paw grafts, lesion volume was not significantly reduced. Hence, functional recovery occurred despite persistence reaching and body sway bias in rats with striatal lesions (unpublished data). The most striking improvements of large lesions, indicating that repair involved mechanisms beyond cell replacement. were seen following left hemisphere stroke (75) . In the sticky tape test of tape removal from forepaws, lesioned/ FUNCTIONAL RECOVERY: sham-grafted rats took about 30 s to contact tape on the FURTHER REQUIREMENTS affected paw and 270-300 s to remove it. Rats with Standardized tests of graft efficacy provide consis-CTX0E03 grafts, like controls, contacted tape on the aftency across studies, and aim to meet regulatory requirefected right paw within 10-15 s and removed it usually ments. However, graft studies offer unrivaled opportuniwithin 250 s (Fig. 3) . These results suggested that grafts ties to investigate repair mechanisms and the functional reduced both sensory neglect attributable to cortical connectivity of brain systems subserving cognitive and damage (contact time) and improved motor coordination motor processes, to provide a more informed basis for disrupted by striatal damage (removal time). Further eviclinical applications. These studies can best be served by dence for improvement of motor asymmetry was shown collaborations across several laboratories and between academic and commercial biotechnologies. Although not necessarily on the regulatory fast track (Fig. 1) , they are important for optimizing graft procedures and understanding graft mechanisms.
Grafting Parameters
Immediate questions involve selection of the optimum number of cells, sites of implantation, and timing of grafts relative to lesion damage and the time course of graft effects, which may vary across different disease models and behavioral tests. Figure 3 . Mean ± SEM time to contact (A) and to remove (B) tape from forepaws, over 5 weeks of testing, 7-12 weeks after ment with amphetamine (2.5 mg/kg, SC). Sham-lesioned controls turned equally often in left and right directions (ϳ50% transplant or sham surgery. Lesioned rats with sham grafts of vehicle (NAC) took 30 s to contact tape on the affected right CCW rotations), whereas lesioned rats with vehicle (NAC) grafts showed a marked leftward bias in 70-80% of turns. Le-paw (p < 0.01 relative to graft and control groups), whereas lesioned rats with CTX0E03 grafts contacted the right paw as sioned rats with CTX0E03 grafts showed a marked reduction in leftward turns (p < 0.001) relative to lesion-only controls, rapidly (within 10-15 s) as sham-lesioned controls. Lesioned rats took 20-40 s longer (p < 0.001) to remove tape from the but remained significantly more biased than sham controls (p < 0.001). affected paw than sham-lesioned and grafted groups.
"Dose response" studies will indicate numbers of fects to be tested, or mice may show physiological problems such as diabetes in the R6 strain of the Huntington cells required for good survival and behavioral efficacy; larger numbers do not necessarily produce better en-mouse (55) , which may interfere with behavioral testing. Transgenic rat models such as the G93A strain for ALS graftment (70) . pathology (34) offer advantages of size, but are more Sites of Grafting. The importance of comparing efexpensive to develop and run than mouse models. Defects of grafts targeted to different sites was underlined spite problems in developing transgenic models, these by the findings (62) that MHP36 cells grafted into the provide the closest approximation to neurodegenerative striatum improved sensory motor function in tape redisease for assessing graft effects. moval, but failed to improve water maze learning, Effects of Practice and Prior Experience. Practice whereas the opposite pattern of effects was found after has a profound impact on graft activity. Döbrössy and intraventricular grafts, following MCAO. Hence, multi-Dunnett (16) found that pretraining rats in paw reaching ple implant sites to target several regions appear to be with the contralateral paw, later impaired by a unilateral important for reaching the multiple systems affected by striatal lesion, exacerbated the lesion, reduced the develstroke damage.
opment of striatal-like neurons in grafts, and diminished Delayed Grafting. Delayed grafting is of clinical relgraft recovery. However, giving rats forced choice trials evance, because graft surgery would typically be underimproved paw reaching, implying that therapy aiming to taken after brain damage has already occurred, or is oncompensate for deficits by using spared functions might going. We typically graft 2-3 weeks after lesion or be less effective than specific training to use impaired ischemic damage in rats, to allow time for recovery and functions targeted by grafts. regaining of preoperative weight. However, in rats with Improved Assessment of Functions. Standardized test bilateral lesions to cholinergic projections, MHP36 batteries are essential for cross-experimental comparigrafts improved water maze learning even when imsons. Alongside these, laboratories are developing methplanted 6 months after lesioning (24) , although they ods for fractionating functions, such as crossed lesions to failed to improve spatial dysfunction when grafted 6 measure selective functions and interactions of different months after hippocampal damage induced by 4VO (H. parts of a mnemonic or motor system (80, 81) , or selec-Hodges, unpublished data). Hence, studies are required tive lesions, imaging, and early gene expression to tease to define the optimum time points for grafting in differapart the neural components of memory and perception ent models.
(1). Use of primates allows difficult cognitive tasks to The Time Course of Graft Effects. Different behavbe performed over a longer time period than is feasible ioral effects and mechanisms of graft action appear to with rats (80, 81) . In turn, selective restoration of funcdevelop over different intervals. For example, reduction tions by grafts offers a novel way to elucidate neural in stroke lesion volume is not significant 3 months after substrates, showing, for example, that the hippocampus grafting (62) but is very substantial by 11 months (92), is important for learning and retrieval, but not storage, implying a reduction in slowly developing secondary of conditional information (96) . damage in grafted animals, rather than acute neuropro-Histological Investigations tection. Some behavioral effects, such as improvement in learning new conditional discriminations in marmo-Cell-Specific Differentiation. Standard histology seeks sets, appeared gradually over testing; others, such as reto demonstrate that grafted cells are present and have call of previously learned discriminations, were apparent differentiated into major cell types. It is also important at first testing (96) . Repeated testing from early after to know that cells differentiate into specific subtypes, grafting will indicate the extent to which animals must relevant to particular neurodegenerative conditions, so "learn to use" their grafts (57) , with implications for that correlations can be calculated between cell numbers postgraft training and physiotherapy in the clinic. and behavioral scores. MHP36 cells, for example, differentiate into normal striatal phenotypes, in roughly the Development of More Refined Models for Assessing proportions found in normal brain (62) , and DARPP-Functional Effects 32+ neurons correlated with improvements in motor tasks (29). The double and triple labeling required for Transgenic Animals. Transgenic mouse models are multiple identification of cells is increasingly facilitated becoming increasingly useful for looking at graft effects by developments in confocal fluorescence microscopy in brains that exhibit developing neurodegenerative pa- (64, 65) . thology, using validated mouse test batteries for functional assessment. Models must be selected with care, Connectivity and Migration. Even when specific cell types have been identified, it remains to be seen what because functional deficits may manifest late, and end stage pathology develops too rapidly to enable graft ef-kind of connectivity they establish within host brain, which could range from integration into host circuits occurrence of host-derived dividing cells is higher than in sham-grafted rats subjected to striatal lesions or focal ("point-to-point" connectivity) to ectopic release of transmitters in terminal regions that compensates for loss of ischemia, even though grafts were sited in the striatum distant from the hippocampus, where the increase in host projections. A number of postmortem and in vitro techniques are available including retrograde and antero-newborn cells was most evident. This is consistent with evidence that stem cell factor increases neurogenesis in grade tracers (98) , tracking graft connections in hippocampal slices (59) , and electrical stimulation of graft vivo (40) and that infusion of trophic factors such as BDNF into the ventricles also stimulates new neuron connections with host cells in whole brain (45, 86) . Imaging cells by MRI provides an important new tool for growth in the parenchyma of several regions, including striatum, thalamus, and hypothalamus, which are distant visualizing the development and resolution of brain damage in relation to changes in behavior (97). In par-from neurogenic regions (74) . There is considerable interest in increasing the neuronal yield and survival of ticular, the use of magnetic contrast agents facilitates tracking of thinly dispersed stem cells so that their distri-grafts by transfection with trophic factors, concurrent infusion of trophic factors in vivo (2, 41, 66) , and in opti-bution can be followed and related to behavioral changes (8, 63) .
mizing growth factor components of graft media during cell preparation. Grafts may also be used as carriers of Changes in Host Brain: apoE Expression trophic factors to reduce ongoing degeneration of ischeand Neurogenesis mic host cells (2, 71) . Hence, trophic mechanisms will play an increasingly important role in stem cell therapy, Effects of grafts on host brain plasticity and reorganization are becoming increasingly well documented, and by priming grafts in vitro, by increasing their survival, differentiation, and integration in vivo, and by enabling indicate that mechanisms for repair include endogenous responses as well as effects of cell replacement. For ex-grafts to rescue damaged host cells. It is important that trophic manipulations are carried out with human cells, ample, the lipid transporter apolipoprotein E (apoE) is upregulated after ischemic and traumatic brain injury, because rodent cells may have a different response profile. LIF and CNTF, for example, enhance proliferation and acts both to clear debris and assist in remodeling of damaged circuits and neuronal sprouting (33,48,87).
of human cells, but promote apoptosis in rodent cells (20). While the 2 and 3 alleles of the APOE gene appear THE "END OF THE BEGINNING" FOR protective, so that apoE-deficient mice show greater cell CLINICAL GRADE STEM CELL LINES loss after global ischemia than controls (32) , and infusions of apoE reduce ischemic damage (31), the 4 allele So far, important initial steps have been taken towards the development of clinical grade lines. Our work is a risk factor for AD (25) , and renders transgenic mice more susceptible to ischemic brain damage (32) . In is-has identified a lead line, CTX0E03, under GLP/GMP conditions, which has been expanded, stored, and banked, chemic rats grafted with MHP36 cells, apoE levels are higher than in those with stroke (MCAO) alone, and ex-survives well in vivo, differentiates primarily into neurons, has a stable and normal karyotype, has shown pression is seen both in host and grafted neurons and astrocytes, and both ipsi-and contralateral to the lesion functional efficacy in ischemic and lesion models, and offers low risk of tumors. Clearly this is only the start (65). Normally following ischemic brain damage, upregulation occurs only around lesions, and is confined to of progress towards clinical trials. There are many ways in which the cells could be developed, their assessment astrocytes. These findings suggest that host apoE is responsive to grafts, and might in turn promote graft sur-refined, and their mechanisms better understood. Research both in academic and commercial biotechnology vival and migration. Conversely, in a host environment deprived of apoE, grafts might show poor survival and settings will make major contributions to the development and control of future stem cell lines. However, it migration and distorted differentiation. Consistent with this suggestion, in apoE-deficient mice, MHP36 stem is important to make a cautious start in clinical grafting, once a candidate line has been identified, in order to cells showed reduced survival and migration compared with wild-type controls, and primarily differentiated into define further steps towards therapy. Regulatory requirements are being clarified, but the issues for novel bio-astrocytes, rather than neurons that predominated in controls (A. Wong, in preparation). Hence, transfection of logical therapies are complex, and countries even differ as to whether use of stem cells per se is permissible. cells with "useful" isoforms of APOE may be required for grafts in patients with the disadvantageous 4 allele,
The indications for phase 1/2 trials must be carefully considered, to select disorders that do not respond to to correct for the lack of receptive host protein.
Brain injury stimulates neurogenesis in the adult conventional treatments, are not so severe as to preclude any chance of improvement, nor deteriorating so rapidly brain (38, 44, 53) . Our observations (S. Patel and I. Reuter, unpublished data) suggest that, in grafted rats, the as to make baseline measurements difficult. A long lead can accompany stem cell research (58) . The biological
